As previously reported, Jefferies upgraded Arvinas (ARVN) to Buy from Hold with a price target of $40, up from $32, after the company and Pfizer (PFE) announced clinical data for vepdegestrant in combination with palbociclib. The firm thinks the combo looks “competitive” and potentially differentiated from peers and believes Pfizer and Arvinas are running “smart trials,” the analyst tells investors. While it is still not fully clear, the firm’s analysis suggests that efficacy is not driven by higher palbociclib exposure, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ARVN:
- Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
- Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
- Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
- Arvinas, Pfizer announce updated Vepdegestrant data to be presented at SABCS
- Arvinas Announces Oversubscribed $350 Million Private Placement
